Evidence map›Paper›PMID 30788041›Full record

ArticleWorld journal of gastrointestinal oncology2019

Feasibility of terahertz imaging for discrimination of human hepatocellular carcinoma.

Feng Duan, Yu-Ye Wang, De-Gang Xu, Jia Shi, Lin-Yu Chen, Li Cui, Yan-Hua Bai, Yong Xu, Jing Yuan, Chao Chang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Feng DuanDepartment of Interventional Radiology, the General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
Yu-Ye WangInstitute of Laser and Optoelectronics, School of Precision Instruments and Optoelectronic Engineering, Key Laboratory of Optoelectronic Information Science and Technology (Ministry of Education), Tianjin University, Tianjin 300072, China.
De-Gang XuInstitute of Laser and Optoelectronics, School of Precision Instruments and Optoelectronic Engineering, Key Laboratory of Optoelectronic Information Science and Technology (Ministry of Education), Tianjin University, Tianjin 300072, China.
Jia ShiInstitute of Laser and Optoelectronics, School of Precision Instruments and Optoelectronic Engineering, Key Laboratory of Optoelectronic Information Science and Technology (Ministry of Education), Tianjin University, Tianjin 300072, China.
Lin-Yu ChenInstitute of Laser and Optoelectronics, School of Precision Instruments and Optoelectronic Engineering, Key Laboratory of Optoelectronic Information Science and Technology (Ministry of Education), Tianjin University, Tianjin 300072, China.
Li CuiDepartment of Interventional Radiology, the General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
Yan-Hua BaiDepartment of Interventional Radiology, the General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
Yong XuDepartment of Hepatobiliary and Pancreatic Surgical Oncology the General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
Jing YuanDepartment of Pathology, the General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
Chao ChangAdvanced Interdisciplinary Technology Research Center, National Innovation Institute of Defense Technology, Beijing 100071, China. changc@xjtu.edu.cn.
People's Liberation Army No. 150 Hospital · CNChinese People's Liberation Army · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide, and novel methods for early/rapid diagnosis of HCC are needed. Terahertz (THz) spectroscopy is considered to have the potential to distinguish between normal liver tissue and HCC tissue; however, there are few reports on it. We conduct this observational study to explore the feasibility of THz imaging for the diagnosis of HCC.

aimTo evaluate the feasibility of THz for discriminating between HCC and normal liver tissues using fresh tissue specimens obtained from HCC patients who had undergone surgery.

methodsNormal liver tissue and HCC tissue were cryosectioned into 50 μm-thick slices and placed on cover glass. Two adjacent tissue sections were separated subjected to histopathological examination by hematoxylin and eosin staining or THz transmission examination, and THz images were compared with pathologically mapped images. We determined the typical tumor and normal liver tissue regions by pathological examination; the corresponding areas of adjacent sections were examined by THz transmission.

resultsThe transmission rate of HCC tissue was 0.15-0.25, and the transmission rate of typical HCC tissue was about 0.2. THz transmittance in normal liver tissue is slightly higher than 0.4, but there were many influencing factors, including the degree of liver cirrhosis, fat components, ice crystals in frozen sections, and apoptosis.

conclusionIn conclusion, this study shows that THz imaging can detect HCC tissue. Further research will yield more detailed data of the THz transmission rates of HCC tissue with different degrees of differentiation.

Indexed as

Hematoxylin and eosin stainingHepatocellular carcinomaLiver pathologyTerahertz imagingTerahertz transmittance

Identifiers

PMID30788041
PMCPMC6379755
OpenAlexW2912969808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.